873054-75-2

Usage

Uses

Used in Pharmaceutical Industry:
[5-[(4-oxo-1H-quinolin-3-yl)carbonylamino]-2-tert-butylphenyl]methylaminoformic acid tert-butyl ester is used as a potential candidate in the pharmaceutical industry for its possible applications in medicinal chemistry and drug development. Its unique structure and functional groups may allow it to interact with biological targets, potentially leading to the discovery of new therapeutic agents.
Used in Research and Development:
In the field of research and development, [5-[(4-oxo-1H-quinolin-3-yl)carbonylamino]-2-tert-butylphenyl]methylaminoformic acid tert-butyl ester can be utilized as a starting material or a building block for the synthesis of more complex molecules with specific biological activities. Its structural features may provide insights into the design of novel compounds with improved pharmacological properties.

Upstream product

• 873056-31-6 tert-butyl 2-tert-butyl-5-nitrobenzylcarbamate 
• 873056-30-5 (2-tert-butyl-5-nitrophenyl)methanamine 
• 873056-32-7 tert-butyl 2-tert-butyl-5-aminobenzylcarbamate 
• 13721-01-2 4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 3282-56-2 4-tert-butylnitrobenzene 

Downstream Products

• 873054-01-4 N-[3-(aminomethyl)-4-tert-butyl-phenyl]-4-oxo-1H-quinoline-3-carboxamide 

Relevant academic research and scientific papers

Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator

Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.